HeyJaredJacob Bell
- Indexed articles, last 90 days
- 7
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Yahoo Finance
- Top 1K sites
- Earliest in this view
- Jul 22, 2026
Latest articles
Sanofi, Regeneron broaden alliance to find their next Dupixent (opens the original)
Read excerpt
The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent. Sanofi and Regeneron have expanded a longstanding alliance in the hopes of developing new immune system-regulating drugs in the vein of their megablockbuster product Dupixent. Per terms of their revised alliance, the companies will co-develop and co-commercialize four long-acting, Regeneron-invented antibodies
This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree (opens the original)
Read excerpt
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. This is the third installment in a new series where BioPharma Dive uses data visualization to recap what's going on across the industry. Today, we're looking at a rush of both reverse mergers and RA Capital financings, as well as a steep stock slide for Novartis. An already prolific investor in biotechnology companies, RA Capital Management has been on
Michael Polansky has a new, skin-focused biotech. Don’t call it a drug company. (opens the original)
Read excerpt
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The harvested skin tissue is taken to a lab where, through a series of closely guarded technologies and techniques, it's kept alive for around a month. And not just alive — resilient. The samples still look and behave like skin, holding onto their structure as well as the resident immune cells that detect pathogens and injuries and regulate inflammatio
Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal (opens the original)
Read excerpt
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Jazz Pharmaceuticals has agreed to buy a San Diego-based biotechnology company developing treatments for genetic epilepsies, through a deal that could be worth just over $1.3 billion. Terms hold that privately held Actio Biosciences will receive $820 million up front and be eligible for $500 million in additional payments if its research programs hit c
Vertex’s biggest overhang: a rival 50 times smaller (opens the original)
Read excerpt
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Vertex Pharmaceuticals became one of the world's largest biotechnology companies thanks to a series of successful cystic fibrosis drugs that have helped many patients live longer, better lives. A fresh earnings report shows those drugs remain on an upward trajectory, with revenue from them increasing by double digits in the second quarter to crest abov
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1K sites
For Yahoo Finance, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.